Massachusetts Society of Clinical Oncologists - FDA grants accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY) for patients with hepatocellular carcinoma (HCC)

"The voice for cancer physicians and their patients in Massachusetts."

Home
Resources
FDA Approvals
FDA grants accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY) for patients with hepatocellular carcinoma (HCC)

FDA grants accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY) for patients with hepatocellular carcinoma (HCC)

11 Mar 2020 4:11 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to the combination of nivolumab and ipilimumab (OPDIVO and YERVOY, Bristol-Myers Squibb Co.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org